Cargando…
COVID‐19: From pathogenesis models to the first drug trials
The number of people infected with SARS‐CoV‐2, and sadly dying from COVID‐19, has exploded, and so the amount of literature on the novel coronavirus and the disease it causes has increased proportionately. The case numbers in some countries are beyond the epidemic peak, but the uncertainty about a s...
Autor principal: | Brüssow, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361915/ https://www.ncbi.nlm.nih.gov/pubmed/32573950 http://dx.doi.org/10.1111/1751-7915.13611 |
Ejemplares similares
-
COVID‐19: vaccine’s progress
por: Brüssow, Harald
Publicado: (2021) -
What we can learn from the dynamics of the 1889 ‘Russian flu’ pandemic for the future trajectory of COVID‐19
por: Brüssow, Harald
Publicado: (2021) -
COVID‐19 and children: medical impact and collateral damage
por: Brüssow, Harald
Publicado: (2022) -
COVID‐19: emergence and mutational diversification of SARS‐CoV‐2
por: Brüssow, Harald
Publicado: (2021) -
Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?
por: Brüssow, Harald
Publicado: (2022)